{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:22:13Z","timestamp":1751570533791},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.lungcan.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T18:05:17Z","timestamp":1515780317000},"page":"38-43","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium"],"prefix":"10.1016","volume":"117","author":[{"given":"David R.","family":"Spigel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna L.","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek M.","family":"Mekhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Zubkus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey B.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.01.007_bib0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1349-7006.1989.tb02247.x","article-title":"Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts","volume":"80","author":"Morisada","year":"1989","journal-title":"Jpn. J. Cancer Res."},{"issue":"Suppl","key":"10.1016\/j.lungcan.2018.01.007_bib0015","first-page":"18s","article-title":"Phase II trial of amrubicin in patients with previously treated small cell lung cancer","volume":"24","author":"Kato","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0020","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2006.08.4145","article-title":"Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301","volume":"24","author":"Onoda","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment for patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0030","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1200\/JCO.2008.18.1974","article-title":"Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402","volume":"26","author":"Inoue","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0035","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/annonc\/mdp384","article-title":"A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405","volume":"21","author":"Inoue","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eishenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.01.007_bib0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0050","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/JTO.0b013e3181a52946","article-title":"A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-stage small-cell lung cancer","volume":"4","author":"Fukuda","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0055","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0060","series-title":"Pass 2008","author":"Hintze","year":"2008"},{"key":"10.1016\/j.lungcan.2018.01.007_bib0065","series-title":"Statistical Methods for Survival Data Analysis","author":"Lee","year":"2007"},{"key":"10.1016\/j.lungcan.2018.01.007_bib0070","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomics results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0075","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Neill","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0080","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"Von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.007_bib0085","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2013.53.5153","article-title":"Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509","volume":"32","author":"Satouchi","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T18:25:58Z","timestamp":1535135158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218300072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":17,"alternative-id":["S0169500218300072"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}